Table 3

(A) Characteristics of chronic HCV-infected patients diagnosed with compensated cirrhosis in Scotland between 1 January 2011 and 31 March 2018, (B) number (and rate) of and (C) HR for new presentation with HCV-related DC among this cirrhotic population according to DAA era of cirrhosis diagnosis and other covariates

(A) Cirrhosis population(B) New presentation with HCV-related DC(C) HR for new presentation with
HCV-related DC (95% CI)
N (%)Person-yearsNRate (per 100 person-years)UnadjustedAdjusted
All patients2249 (100)67382193.25
Diagnosed with cirrhosisPre-DAA era1015 (45)45291593.511.001.00
DAA era1234 (55)2209602.720.59 (0.43 to 0.80)0.55 (0.40 to 0.76)
SexFemale584 (26)1769593.331.001.00
Male1665 (74)49691603.220.96 (0.71 to 1.30)0.93 (0.68 to 1.27)
Age (years) at cirrhosis diagnosis (years)<501402 (62)43311222.821.001.00
50+847(38)2407974.031.40 (1.07 to 1.83)1.61 (1.19 to 2.20)
Past/Current risk groupPWID1448 (64)43041293.001.001.00
Non-PWID348 (15)1166363.091.08 (0.77 to 1.50)0.96 (0.63 to 1.46)
Not known*453 (20)1268544.26
Alcohol consumption history>50 units/week743 (33)22071024.621.78 (1.37 to 2.32)1.67 (1.26 to 2.20)
≤50 units/week (and not known)1506 (67)45311172.581.001.00
GenotypeG1930 (41)2752923.341.09 (0.82 to 1.45)1.03 (0.77 to 1.38)
G31041 (46)3243983.021.001.00
Other/NK278 (12)743293.901.27 (0.84 to 1.92)1.01 (0.65 to 1.57)
Child-Pugh classA1556 (69)47521312.761.001.00
B62 (3)1341410.474.03 (2.14 to 7.59)3.95 (1.98 to 1.57)
Not known*631 (28)1852744.00
Prior antiviral treatmentNaïve1876 (83)51771763.401.001.00
Experienced373 (17)1562432.750.86 (0.62 to 1.21)0.75 (0.52 to 1.06)
  • *Category not used in Cox regression as missing values were imputed (see ‘Methods’ section).

  • DAA, direct-acting antiviral; DC, decompensated cirrhosis; NK, not known; PWID, person who injects drugs.